Skip to main content
Erschienen in: Clinical Rheumatology 7/2023

10.03.2023 | BRIEF REPORT

Brachial artery flow-mediated dilation in patients with systemic sclerosis: an experience from tertiary care center from North India

verfasst von: Kavita Poonia, Mala Bhalla, Kanika Dogar, Anita Malhotra, Kajal Aggarwal

Erschienen in: Clinical Rheumatology | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Role of flow-mediated dilatation (FMD) testing in the assessment of the macrovascular dysfunction in systemic sclerosis (SS) and correlation of FMD values with disease severity. Twenty-five patients of SS and 25 healthy age-matched controls were recruited. Modified Rodnan skin thickness score (MRSS) was used for skin thickness assessment. FMD values were measured in the brachial artery. FMD values done at baseline before the initiation of treatment were lower in SSc patients (4.044 ± 2.742) compared to the healthy controls (11.076 ± 5.896) (P < 0.05). Comparison of FMD values between patients with limited cutaneous systemic sclerosis (LSSc) and diffuse cutaneous systemic sclerosis (DSSc) showed a trend toward lower in LSSc (3.182 ± 2.482) as compared to DSSc patients (5.111 ± 2.711); however, the difference was not statistically significant. Patients with lung manifestations on high-resolution CT chest showed lower FMD values (2.66 ± 2.23) compared to those without HRCT changes (6.45 ± 2.56) (P < 0.05). We demonstrate that FMD values in SSc patients were lower when compared to healthy controls. Patients with SS having pulmonary manifestations showed a lower value of FMD.
Key Points
FMD is a simple non-invasive tool to assess the endothelial function in patients with systemic sclerosis.
Lower values of FMD in systemic sclerosis suggest that the endothelial dysfunction and values can also be correlated with other organ involvement such as lung and skin involvement. So, lower FMD values might be a useful marker for disease severity.
Literatur
1.
2.
3.
Zurück zum Zitat Harris RA, Nishiyama SK, Wray DW, Richardson RS (2010) Ultrasound assessment of flow-mediated dilation. Hypertension 55:1075–1085CrossRefPubMed Harris RA, Nishiyama SK, Wray DW, Richardson RS (2010) Ultrasound assessment of flow-mediated dilation. Hypertension 55:1075–1085CrossRefPubMed
4.
Zurück zum Zitat Takahashi T, Asano Y, Amiya E, Hatano M, Tamaki Z, Ozeki A et al (2012) Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases. Mod Rheumatol 22:598–601CrossRefPubMed Takahashi T, Asano Y, Amiya E, Hatano M, Tamaki Z, Ozeki A et al (2012) Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases. Mod Rheumatol 22:598–601CrossRefPubMed
5.
Zurück zum Zitat Frech TM, Murtaugh MA (2019) Non-invasive digital thermal monitoring and flow-mediated dilation in systemic sclerosis. Clin Exp Rheumatol 119:97–101 Frech TM, Murtaugh MA (2019) Non-invasive digital thermal monitoring and flow-mediated dilation in systemic sclerosis. Clin Exp Rheumatol 119:97–101
6.
Zurück zum Zitat Frech T, Walker AE, Barrett-O’Keefe Z, Hopkins PN, Richardson RS, Wray DW et al (2015) Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction. Clin Rheumatol 34:905–13CrossRefPubMed Frech T, Walker AE, Barrett-O’Keefe Z, Hopkins PN, Richardson RS, Wray DW et al (2015) Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction. Clin Rheumatol 34:905–13CrossRefPubMed
7.
Zurück zum Zitat Rollando D, Bezante GP, Sulli A, Balbi M, Panico N, Pizzorni C et al (2010) Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment. J Rheumatol 37:1168–1173CrossRefPubMed Rollando D, Bezante GP, Sulli A, Balbi M, Panico N, Pizzorni C et al (2010) Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment. J Rheumatol 37:1168–1173CrossRefPubMed
8.
Zurück zum Zitat Silva I, Loureiro T, Teixeira A, Almeida I, Mansilha A, Vasconcelos C et al (2015) Digital ulcers in systemic sclerosis: role of flow-mediated dilatation and capillaroscopy as risk assessment tools. Eur J Dermatol 25:444–451CrossRefPubMed Silva I, Loureiro T, Teixeira A, Almeida I, Mansilha A, Vasconcelos C et al (2015) Digital ulcers in systemic sclerosis: role of flow-mediated dilatation and capillaroscopy as risk assessment tools. Eur J Dermatol 25:444–451CrossRefPubMed
9.
Zurück zum Zitat Cypienė A, Laucevicius A, Venalis A, Dadonienė J, Ryliskytė L, Petrulionienė Z et al (2008) The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin Rheumatol 27:1517–1522CrossRefPubMed Cypienė A, Laucevicius A, Venalis A, Dadonienė J, Ryliskytė L, Petrulionienė Z et al (2008) The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin Rheumatol 27:1517–1522CrossRefPubMed
10.
Zurück zum Zitat Pacholczak-Madej R, Kuszmiersz P, Bazan-Socha S, Kosałka-Węgiel J, Iwaniec T, Zaręba L et al (2020) Endothelial dysfunction in patients with systemic sclerosis. Adv Dermatol Allergol 37:495–502CrossRef Pacholczak-Madej R, Kuszmiersz P, Bazan-Socha S, Kosałka-Węgiel J, Iwaniec T, Zaręba L et al (2020) Endothelial dysfunction in patients with systemic sclerosis. Adv Dermatol Allergol 37:495–502CrossRef
11.
Zurück zum Zitat González-Martín JJ, Novella-Navarro M, Calvo-Aranda E, Cabrera-Alarcón JL, Carrión O, Abdelkader A et al (2020) Endothelial dysfunction and subclinical atheromatosis in patients with systemic sclerosis. Clin Exp Rheumatol 125:48–52 González-Martín JJ, Novella-Navarro M, Calvo-Aranda E, Cabrera-Alarcón JL, Carrión O, Abdelkader A et al (2020) Endothelial dysfunction and subclinical atheromatosis in patients with systemic sclerosis. Clin Exp Rheumatol 125:48–52
12.
Zurück zum Zitat Fernandes TM, Bica BEG, Villela NR, Salles EF, de Azevedo MNL, de Papi JAS et al (2012) Evaluation of endothelial function in patients with limited systemic sclerosis by use of brachial artery Doppler ultrasound. Rev Bras Reumatol 52:561–8CrossRefPubMed Fernandes TM, Bica BEG, Villela NR, Salles EF, de Azevedo MNL, de Papi JAS et al (2012) Evaluation of endothelial function in patients with limited systemic sclerosis by use of brachial artery Doppler ultrasound. Rev Bras Reumatol 52:561–8CrossRefPubMed
13.
Zurück zum Zitat Andersen GN, Mincheva-Nilsson L, Kazzam E, Nyberg G, Klintland N, Petersson AS et al (2002) Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production: Assessment of Vascular Function in SSc. Arthritis Rheum 46:1324–1332CrossRefPubMed Andersen GN, Mincheva-Nilsson L, Kazzam E, Nyberg G, Klintland N, Petersson AS et al (2002) Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production: Assessment of Vascular Function in SSc. Arthritis Rheum 46:1324–1332CrossRefPubMed
14.
Zurück zum Zitat Roustit M, Simmons GH, Baguet JP, Carpentier P, Cracowski JL (2008) Discrepancy between simultaneous digital skin microvascular and brachial artery macrovascular post-occlusive hyperemia in systemic sclerosis. J Rheumatol 35:1576–83PubMedPubMedCentral Roustit M, Simmons GH, Baguet JP, Carpentier P, Cracowski JL (2008) Discrepancy between simultaneous digital skin microvascular and brachial artery macrovascular post-occlusive hyperemia in systemic sclerosis. J Rheumatol 35:1576–83PubMedPubMedCentral
15.
Zurück zum Zitat Rajagopalan S, Pfenninger D, Kehrer C, Chakrabarti A, Somers E, Pavlic R et al (2003) Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud’s phenomenon: Implications for vascular dysfunction and progression of disease. Arthritis Rheum 48:1992–2000CrossRefPubMed Rajagopalan S, Pfenninger D, Kehrer C, Chakrabarti A, Somers E, Pavlic R et al (2003) Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud’s phenomenon: Implications for vascular dysfunction and progression of disease. Arthritis Rheum 48:1992–2000CrossRefPubMed
16.
Zurück zum Zitat Masi AT (1980) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–90CrossRef Masi AT (1980) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–90CrossRef
18.
Zurück zum Zitat Constans J, Gosse P, Pellegrin JL, Ansoborlo P, Leng B, Clémenty J et al (1997) Alteration of arterial distensibility in systemic sclerosis. J Intern Med 241:115–118CrossRefPubMed Constans J, Gosse P, Pellegrin JL, Ansoborlo P, Leng B, Clémenty J et al (1997) Alteration of arterial distensibility in systemic sclerosis. J Intern Med 241:115–118CrossRefPubMed
19.
Zurück zum Zitat Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. The Lancet 340:1111–1115CrossRef Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. The Lancet 340:1111–1115CrossRef
20.
Zurück zum Zitat Peretz A, Leotta DF, Sullivan JH, Trenga CA, Sands FN, Aulet MR et al (2007) Flow mediated dilation of the brachial artery: an investigation of methods requiring further standardization. BMC Cardiovasc Disord 7:11CrossRefPubMedPubMedCentral Peretz A, Leotta DF, Sullivan JH, Trenga CA, Sands FN, Aulet MR et al (2007) Flow mediated dilation of the brachial artery: an investigation of methods requiring further standardization. BMC Cardiovasc Disord 7:11CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Rongen GA, van Ingen I, Kok M, Vonkeman H, Janssen M, Jansen TL (2018) Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs. Clin Rheumatol 37:909–916CrossRefPubMed Rongen GA, van Ingen I, Kok M, Vonkeman H, Janssen M, Jansen TL (2018) Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs. Clin Rheumatol 37:909–916CrossRefPubMed
22.
Zurück zum Zitat van der Horst-Bruinsma IE, Nurmohamed MT (2012) Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis 4:413–22CrossRefPubMedPubMedCentral van der Horst-Bruinsma IE, Nurmohamed MT (2012) Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis 4:413–22CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S (1998) Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud’s phenomenon secondary to systemic sclerosis. Am J Cardiol 82:1555–1557CrossRefPubMed Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S (1998) Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud’s phenomenon secondary to systemic sclerosis. Am J Cardiol 82:1555–1557CrossRefPubMed
24.
Zurück zum Zitat Mulkoju R, Saka VK, Rajaram M, Kumari R, Negi VS, Mohanty Mohapatra M, et al. (2020) Pulmonary manifestations in systemic sclerosis: hospital-based descriptive study. Cureus 16 Mulkoju R, Saka VK, Rajaram M, Kumari R, Negi VS, Mohanty Mohapatra M, et al. (2020) Pulmonary manifestations in systemic sclerosis: hospital-based descriptive study. Cureus 16
25.
Zurück zum Zitat Bhattacharjee D, Mondal S, Saha A, Misra S, Chatterjee S, Rao A, et al. (2022) Effect of vasodilator and immunosuppressive therapy on the endothelial dysfunction in patients with systemic sclerosis. Clin Exp Med 25. Bhattacharjee D, Mondal S, Saha A, Misra S, Chatterjee S, Rao A, et al. (2022) Effect of vasodilator and immunosuppressive therapy on the endothelial dysfunction in patients with systemic sclerosis. Clin Exp Med 25.
Metadaten
Titel
Brachial artery flow-mediated dilation in patients with systemic sclerosis: an experience from tertiary care center from North India
verfasst von
Kavita Poonia
Mala Bhalla
Kanika Dogar
Anita Malhotra
Kajal Aggarwal
Publikationsdatum
10.03.2023
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 7/2023
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-023-06562-3

Weitere Artikel der Ausgabe 7/2023

Clinical Rheumatology 7/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.